Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Cite this paper

@article{QuintsCardama2010PreclinicalCO, title={Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.}, author={Alfonso Quint{\'a}s-Cardama and Kris Vaddi and Phillip C.C. Liu and Taghi Manshouri and Jun Li and Peggy A. Scherle and Eian Caulder and Xiaoming Wen and Yanlong Li and Paul Waeltz and Mark J. Rupar and Timothy C. Burn and Yvonne Y Lo and Jennifer A Kelley and Maryanne B. Covington and Stacey Shepard and James D. Rodgers and Patrick J. Haley and Hagop M. Kantarjian and Jordan S. Fridman and Srdan Verstovsek}, journal={Blood}, year={2010}, volume={115 15}, pages={3109-17} }